Follow-up of patients with vertically-acquired HIV infection who are more than 9 years old

Journal of Tropical Pediatrics

Volumn 49, Issue 4, 2003, Pages 253-255

  Rotta, N T ^a   Silva, A R ^a   Silva, C L ^a   Silva, F F ^a   Silva, M G ^a   Santos, L O ^a   Kelbert, S ^a   Ohlweiler, L ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; CD4 ANTIGEN; ZIDOVUDINE;

ARTICLE; BIOLOGICAL MONITORING; CELL COUNT; CHILD; CHILDHOOD MORTALITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; ELECTROENCEPHALOGRAM; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; ONSET AGE; OUTCOMES RESEARCH; POPULATION RESEARCH; PROGNOSIS; QUALITY OF LIFE; RETROSPECTIVE STUDY; SOCIAL ASPECT; SURVIVAL RATE; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

AIDS DEMENTIA COMPLEX; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAZIL; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DISEASE TRANSMISSION, VERTICAL; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INFANT; MALE; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0042127160     PISSN: 01426338     EISSN: None     Source Type: Journal    
DOI: 10.1093/tropej/49.4.253     Document Type: Article

References (13)

1. Davis SF, Byers RH Jr, Lindegren ML, et al. Prevalence and incidence of vertically acquired HIV infection in the United States. JAMA 1995; 274: 952-55.
2. Mofenson L. Epidemiology and determinants of vertical HIV transmission. Semin Pediatr Infect Dis 1994; 5: 252-65.
3. Connor EM, Sperling, RS, Gelber, R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331: 1173-80.
4. The European Collaborative Study. Natural history of vertically acquired human immunodeficiency virus type 1 infection. Pediatrics 1994; 94: 815-19.
5. Englund JÁ, Baker CJ, Raskino C, et al. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. N Engl J Med 1997; 336: 1704-12.
6. Grubman S. Older children and adolescents living with perinatally acquired human immunodeficiency virus infection. Pediatrics 1995; 95: 657-63.
7. Rotta NT, Silva C, Ohlweiler L, et al. Manifestaciones neurológicas del sida en la infancia. Rev Neurol 1999; 29: 319-22.
8. Cooper ER, Hanson C, Diaz C, et al. Encephalopathy and progression of human immunodeficiency virus disease in a cohort of children with perinatally acquired human immunodeficiency virus infection. J Pediatr 1998; 132: 808-12.
9. Epstein LG, Sharer LR, Toshi W, et al. Progressive encephalopathy in children with acquired immune deficiency syndrome. Ann Neurol 1985; 17: 488-96.
10. Johann-Liang R, Lin K, Cervia J, Stavola J, Noel G. Neuroimaging findings in children perinatally infected with the human immunodeficiency virus. Pediatr Infect Dis J 1998; 17: 353-54.
11. Tellechea-Rotta N, de Silva CLO, Colvero M, Schirmer M, Afonso-Galvão N. Neurosida. Rev Neurol 1997; 25: 903-5.
12. Ojukwu IC, Epstein LG. Neurologic manifestations of infection with HIV. Pediatr Infect Dis J 1998; 17: 341-44.
13. Raskino C, Pearson DA, Baker CJ, et al. Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatrics 2000; 104: e32.